Myelomastocytic leukemia: histopathological features, diagnostic criteria and differential diagnosis
Authors:
- Karl SotlarKSKarl Sotlar
- Andreas ReiterARAndreas Reiter
- Peter ValentPeter Valent
- 22 May 2014
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 7 (4) , 431-437
Abstract
Myelomastocytic leukemia (MML) is an extremely rare myeloid overlap-neoplasm that belongs to the group of tryptase-positive (T+) myeloid neoplasms. Main differential diagnoses include aggressive systemic mastocytosis (ASM), in particular ASM in transformation; mast cell leukemia; T+ acute myeloid leukemia (T+ AML); acute basophilic leukemia and chronic basophilic leukemia. MML exhibits both proliferative and dysplastic features and is characterized by prominent differentiation into the mast cell lineage in an advanced myeloid neoplasm, usually primary or secondary AML. While the histological key feature of MML is a diffuse increase in neoplastic cells expressing mast cell-related antigens like tryptase and CD117 (KIT), the most important cytomorphological finding in bone marrow (BM) and peripheral blood (PB) is the metachromatically granulated blast cell (= metachromatic blast). In contrast to systemic mastocytosis (SM), MML neither shows activating point mutations at codon 816 of KIT nor the aberrant expression of CD25 by mast cells is seen. MML can only be diagnosed when tryptase-staining is performed on BM biopsy specimens, PB and BM smears are investigated for presence of metachromatic blasts and other T+ leukemias have been excluded.Keywords
This publication has 14 references indexed in Scilit:
- Myelomastocytic Leukemia With t(8;21) in a 3-year-old ChildJournal of Pediatric Hematology/Oncology, 2011
- Eosinophil, basophil, and mast cell infiltrates in the bone marrow: crossing the boundaries of diagnosisJournal of Hematopathology, 2011
- Differential Diagnoses of Systemic Mastocytosis in Routinely Processed Bone Marrow Biopsy Specimens: A ReviewPathobiology, 2010
- Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: A diagnostic challengeAmerican Journal of Hematology, 2010
- Standards and standardization in mastocytosis: Consensus Statements on Diagnostics, Treatment Recommendations and Response CriteriaEuropean Journal of Clinical Investigation, 2007
- The tryptase positive compact round cell infiltrate of the bone marrow (TROCI-BM): a novel histopathological finding requiring the application of lineage specific markersJournal of Clinical Pathology, 2006
- Myelomastocytic Leukemia: Evidence for the Origin of Mast Cells from the Leukemic Clone and Eradication by Allogeneic Stem Cell TransplantationClinical Cancer Research, 2005
- Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challengeJournal of Clinical Pathology, 2004
- Myelomastocytic leukemia: myeloid neoplasm characterized by partial differentiation of mast cell-lineage cellsThe Hematology Journal, 2002
- Tryptase a Novel Biochemical Marker of Acute Myeloid LeukemiaLeukemia & Lymphoma, 2002